间歇性高剂量的齐多夫丁.

Effect of palbociclib plus letrozole on patient-reported health-related quality of life: extended follow-up of the PALOMA-2 trial.

ESMO open·2025

Drug-drug interactions between palbociclib and proton pump inhibitors in early breast cancer: an exploratory analysis of PALLAS (ABCSG-42/AFT-05/BIG-14-13/PrE0109).

ESMO open·2025

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2022

ESO-ESMO fifth international consensus guidelines for breast cancer in young women (BCY5).

Annals of oncology : official journal of the European Society for Medical Oncology·2022

ESO-ESMO 4th International Consensus Guidelines for Breast Cancer in Young Women (BCY4).

Annals of oncology : official journal of the European Society for Medical Oncology·2020

Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up.

Breast cancer research and treatment·2019

1-month versus 12-month dual antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation (OPTIMA-AF): a multicentre, open-label, hybrid non-inferiority and superiority, randomised, controlled trial.

Lancet (London, England)·2026

Multidomain lifestyle intervention for the prevention of cognitive decline in at-risk older adults in Latin America (LatAm-FINGERS): a single-blind, multicentre, randomised controlled trial.

Lancet (London, England)·2026

Advancing the relevance of clinical trials for older patients.

Lancet (London, England)·2026

Temocillin versus carbapenems for bacteraemia due to third-generation cephalosporin-resistant Enterobacterales in Spain (ASTARTÉ): a multicentre, phase 3, open-label, non-inferiority, randomised clinical trial.

Lancet (London, England)·2026

Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial.

Lancet (London, England)·2026

Children in all policies: lessons from a global collaboration to promote the health and wellbeing of children and future generations.

Lancet (London, England)·2026

Thermal stability and anisotropic thermal expansion of WS2 annealed in different atmospheres.

RSC advances·2026

Polar anchoring effect-mediated solvation regulation in fluorinated gel polymer electrolytes for high-voltage lithium-ion full batteries.

Materials horizons·2026

Interplay of electrolyte transport, electrode balancing, and cathode loading in rate-dependent behavior of graphite‖NMC532 cells.

Physical chemistry chemical physics : PCCP·2026

Evaluation of Novel Cloxyquin Analogs for K2P18.1 Channel Modulation.

Archiv der Pharmazie·2026

A novel two-dimensional monolayer tetragonal boron carbide as a promising anode for Mg-ion.

Journal of molecular modeling·2026

Ictal phase-amplitude coupling supports surgical decision-making in MRI-negative epilepsy with non-localizing SEEG: an illustrative case.

Acta neurochirurgica·2026

相关实验视频

间歇性高剂量的齐多夫丁

相关概念视频

Effect of palbociclib plus letrozole on patient-reported health-related quality of life: extended follow-up of the PALOMA-2 trial.

Drug-drug interactions between palbociclib and proton pump inhibitors in early breast cancer: an exploratory analysis of PALLAS (ABCSG-42/AFT-05/BIG-14-13/PrE0109).

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer.

ESO-ESMO fifth international consensus guidelines for breast cancer in young women (BCY5).

ESO-ESMO 4th International Consensus Guidelines for Breast Cancer in Young Women (BCY4).

Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up.

1-month versus 12-month dual antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation (OPTIMA-AF): a multicentre, open-label, hybrid non-inferiority and superiority, randomised, controlled trial.

Multidomain lifestyle intervention for the prevention of cognitive decline in at-risk older adults in Latin America (LatAm-FINGERS): a single-blind, multicentre, randomised controlled trial.

Advancing the relevance of clinical trials for older patients.

Temocillin versus carbapenems for bacteraemia due to third-generation cephalosporin-resistant Enterobacterales in Spain (ASTARTÉ): a multicentre, phase 3, open-label, non-inferiority, randomised clinical trial.

Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial.

Children in all policies: lessons from a global collaboration to promote the health and wellbeing of children and future generations.

Thermal stability and anisotropic thermal expansion of WS2 annealed in different atmospheres.

Polar anchoring effect-mediated solvation regulation in fluorinated gel polymer electrolytes for high-voltage lithium-ion full batteries.

Interplay of electrolyte transport, electrode balancing, and cathode loading in rate-dependent behavior of graphite‖NMC532 cells.

Evaluation of Novel Cloxyquin Analogs for K2P18.1 Channel Modulation.

A novel two-dimensional monolayer tetragonal boron carbide as a promising anode for Mg-ion.

Ictal phase-amplitude coupling supports surgical decision-making in MRI-negative epilepsy with non-localizing SEEG: an illustrative case.

相关实验视频

间歇性高剂量的齐多夫丁

相关概念视频

相关文章